regarding information needed by
Campaign audiences as well as their
attitudes and behaviors related to
COVID–19 and the COVID–19 vaccines.
These will be used to inform the
development of Campaign messages and
strategy.

**Copy Testing Surveys**

Prior to placing Campaign
advertisements in market, ASPA will
conduct copy testing surveys to ensure
the final Campaign messages have the
intended effect on target attitudes and
behaviors. Copy testing surveys will be
conducted with sample members who
comprise the target audiences; these
surveys will assess perceived
effectiveness of the advertisements as
well as the effect of exposure to an ad
on key attitudes and behavioral
intentions. The results from these
surveys will be used internally by ASPA
to inform decisions on Campaign
messages and materials; for example, to
identify revisions to the materials or
determine which advertisement to move
to market.

**Need and Proposed Use:** In light of
the current COVID–19 crisis, this
information is needed given the impact
of the pandemic on the nation. The
Secretary of the Department of Health
and Human Services (HHS) has declared
a public health emergency effective
January 27, 2020, under section 319 of
the Public Health Service Act (42 U.S.C.
247d [1]) and renewed it continually
since its issuance (see links to the
determination here and here).
Additionally, in accordance with 5 CFR
1320.13, HHS previously requested
emergency submissions (sections 1320
(a)(2)(ii) and (2)(iii) of the federal
regulations.

### ESTIMATED ANNUALIZED BURDEN HOUR TABLE

<table>
<thead>
<tr>
<th></th>
<th>CET</th>
<th>Foundational focus groups</th>
<th>Copy testing survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hours to screen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening participants (per wave)</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Screening completes (per wave)</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Screening participants (total/screened out)</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Hours to complete survey/group</td>
<td></td>
<td>0.12</td>
<td></td>
</tr>
<tr>
<td>Participants (per wave/round)</td>
<td></td>
<td>1,000</td>
<td></td>
</tr>
<tr>
<td>Number of waves/rounds</td>
<td></td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>Burden per wave/round</td>
<td></td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>Total participants</td>
<td></td>
<td>92,000</td>
<td></td>
</tr>
<tr>
<td>Total respondents *</td>
<td></td>
<td>92,000</td>
<td></td>
</tr>
<tr>
<td>Total burden hours</td>
<td></td>
<td>11,040</td>
<td></td>
</tr>
</tbody>
</table>

*Total respondents = total participants for each effort + total people screened out.

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.

The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Integrated Preclinical/
Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed).

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G36,
Rockville, MD 20892 (Virtual Meeting).

**Contact Person:** Poonam Pegu, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, MSC–9823, Rockville, MD 20892. 240–292–0719, poonam.pegu@nih.gov.

**Catalogue of Federal Domestic Assistance Program Nos.:** 93.855, Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research.

**Dated:** May 28, 2021.

**Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.**

[FR Doc. 2021–11711 Filed 6–3–21; 8:45 am]

BILLING CODE 4140–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

**National Institutes of Health**

**National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting**

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.

The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

**Name of Committee:** National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; SARS-CoV–2, COVID–19

**Date:** July 15–16, 2021.

**Time:** 9:00 a.m. to 6:00 p.m.
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Artificial Intelligence for Multimodal Data Modeling and Biointerfaces Center Review
Date: June 29, 2021.
Time: 9:00 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Amitava Roy, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 904B, Bethesda, MD 20892, (301) 435-9354, amitava.roy@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Human Brain and Child Development Study Consortium Administrative Core and Data Coordinating Center (U24)
Date: June 29, 2021.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ranga Srinivas, Ph.D., Chief, Extramural Project Review Branch, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 6700 B Rockledge Drive, Room 2114, Bethesda, MD 20892, (301) 451-2067, srinivasr@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Center Grants; 93.272, Alcohol Research Service Awards for Researchers Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS)

Dated: June 1, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-11785 Filed 6-3-21; 8:45 am]
BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Genes, Genomes and Genetics
Date: June 29–30, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: John Harold Laity, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 402-8254, jhari@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Genes, Genomes and Genetics
Date: July 1, 2021.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alexander Yakovlev, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5206, MSC 7846, Bethesda, MD 20892–7846, (301) 435–1254, yakovleva@csr.nih.gov.


Tyesha M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-11738 Filed 6-3-21; 8:45 am]
BILLING CODE 4140-01-P